Scientific Advisory Board

---

• Drug Development Advisor

Dr. Cudkowicz is the Director of the Healey Center for ALS, Chief of Neurology at Mass General, and the Julieanne Dorn Professor at Harvard Medical School. On this advisory role at RockGen, Dr. Cudkowicz leverages over three decades of research and clinical activities in taking care of ALS patients and running clinical trials, therapeutic studies to stop ALS. She is one of the founders of the Northeast ALS Consortium and brought innovations to accelerate the development of treatments for people with ALS, including the first antisense oligonucleotide treatment for ALS and adaptive platform trial designs. Dr. Cudkowicz is Principal Investigator of the Clinical Coordination Center for the NINDS Neurology Network of Excellence in Clinical Trials. She is a member of AAP, NAM, and received the American Academy of Neurology Sheila Essay ALS award, the Pinnacle Award from the Boston Chamber of Commerce. 

• Pharmaceutical Advisor

Dr. Bennett is a drug discovery consultant and biotech entrepreneur with a focus on preclinical drug optimization and development, inflammation and autoimmunity, and cell and molecular biology. He worked for the Upjohn Company, and then Signal Pharmaceuticals, later Celgene, for 20 years and was involved in multiple projects including several currently active in the 3 phases of clinical assessment. 

• Scientific Advisor

Dr. Ebrahimzadeh is a neuroscientist with over a decade of experience in neuropharmacology, neurodegenerative disease research, and CNS drug development. At RockGen Therapeutics, he contributes scientific expertise to ALS-focused translational research programs, with particular emphasis on protein misfolding mechanisms, preclinical therapeutic strategy, and computational approaches to neurodegeneration.

His work includes scientific analysis and interpretation of preclinical data, collaborative development of ALS-related research concepts, and co-authoring of ongoing scientific manuscripts focused on protein misfolding, small-molecule stabilization strategies, and AI-enabled computational modeling. He also provides scientific input supporting early-stage grant proposals and intellectual property development related to ALS therapeutics.

Dr. Ebrahimzadeh has collaborated with pharmaceutical and biotechnology organizations across the U.S. and Europe and has contributed to the preclinical and early clinical development of multiple drug candidates. His academic research at institutions including Penn State University has been published in high-impact neuroscience and psychiatry journals and cited in review articles, textbooks, and regulatory science contexts.